Vitamin K deficiency and why newborns get a vitamin K shot at birth
Newborns get a vitamin K shot at birth because they have very small vitamin K reserves and are vulnerable to vitamin K deficiency bleeding (VKDB). The prophylaxis helps prevent this uncommon disorder, which can cause serious haemorrhage in the skin, gastrointestinal tract or brain.
The evidence below follows the biology from clotting function to newborn risk, then examines early, classic and late VKDB and the studies behind prevention. It also distinguishes the relatively firm evidence in term infants from the more limited trial evidence on the best prophylaxis approach for babies born prematurely.
What vitamin K deficiency means for blood clotting
The name vitamin K covers several fat-soluble compounds with a shared biological function. They enable vitamin K-dependent carboxylase to switch key haemostatic proteins into their active forms, including prothrombin (factor II). Without enough vitamin K, these proteins can be produced but remain less able to participate normally in the clotting cascade. If the shortage becomes severe, coagulation can be disrupted and bleeding or easy bruising may follow (Office of Dietary Supplements, 2026).
A varied diet usually provides enough phylloquinone for healthy adults, while menaquinones made by intestinal bacteria may add to overall vitamin K status. Clinically important deficiency is therefore unusual in this group. The pattern changes when absorption or metabolism is disturbed, because vitamin K is fat-soluble and depends on normal digestive handling. Beyond infancy, deficiency is more often associated with impaired fat absorption, gastrointestinal disease, bariatric surgery or medication that disrupts vitamin K metabolism than with an ordinary varied diet (Office of Dietary Supplements, 2026; MedlinePlus, 2025).
Symptoms emerge when vitamin K-dependent clotting is impaired enough for bleeding to occur. The site may be superficial, such as skin or mucous membranes, or involve the umbilical stump, a procedure site, the gastrointestinal tract or internal tissues. That wide range means the disorder does not have one distinctive outward appearance. In infancy, bleeding inside the skull is the most serious presentation, and CDC guidance notes that a life-threatening bleed may develop without an obvious warning sign (Sutor et al., 1999; CDC, 2025).
Why newborns begin life with low vitamin K stores
Newborns naturally arrive with little vitamin K in reserve, which is a physiological starting point rather than a diagnosis of deficiency in every baby. Placental transfer is limited, so the amount carried into birth is small. This makes the newborn period different from later life, when dietary intake and an established intestinal microbiota provide more continuous inputs. The early intestine has not yet developed the mature bacterial community that later contributes menaquinones, adding another reason why reserves remain modest during the first weeks of life (Zipursky, 1999; CDC, 2025).
Early feeding does not rapidly build a large vitamin K reserve because human milk contains only a small amount of the vitamin. Among infants who have not received effective prophylaxis, exclusive breastfeeding is consequently associated with greater susceptibility to late VKDB. This association describes vitamin K exposure in early infancy; it is not an argument against breastfeeding itself. Dietary advice aimed at older children or adults addresses a different physiological setting; the vitamin K explainer covers those dietary forms and functions, while newborn prophylaxis addresses the distinctive risk around birth (Hand et al., 2022; Office of Dietary Supplements, 2026).
Baseline newborn vulnerability can be compounded by other conditions. Medicines taken during pregnancy that interfere with vitamin K are linked with very early VKDB, whereas cholestasis, cystic fibrosis and other causes of malabsorption are important in later cases. Some of these disorders may not be apparent when a baby first leaves maternity care, so a risk-based approach cannot identify every infant who will later become vulnerable. Paediatric guidance therefore recommends prophylaxis for all newborn infants instead of restricting prevention to babies whose added risk factors are already known (Hand et al., 2022; Mihatsch et al., 2016).
- Only a small amount of vitamin K crosses the placenta, so little is carried into the newborn period.
- The early gut microbiota is not yet mature enough to make the menaquinone contribution seen later in life.
- Human milk provides relatively little vitamin K, which limits how quickly stores can accumulate after birth.
- Cholestatic, hepatic and malabsorption disorders can further restrict the vitamin K available to support coagulation.
How vitamin K deficiency bleeding presents in infancy
Early and classic VKDB
Clinicians divide VKDB into age-based forms because each window has a different clinical context. Early VKDB begins within 24 hours of birth and is closely linked to maternal exposure to drugs that disrupt vitamin K activity. The classic form occurs on days 2–7; bleeding in this period may be seen at the umbilicus, in the skin or nose, or from the gastrointestinal tract. The labels describe timing rather than completely separate diseases, but they help distinguish the settings in which bleeding most often develops (CDC, 2025; Puckett & Offringa, 2000).
Late VKDB and intracranial bleeding
The late form begins after the first week of life and remains possible until about 6 months, with many cases occurring during the first two months. CDC guidance reports intracranial haemorrhage in 30% to 60% of late cases, often without a preceding minor bleed. That distribution explains why late VKDB is considered dangerous despite being uncommon: the first recognised event may already involve the brain. Risk is particularly linked to exclusive breastfeeding in the absence of effective prophylaxis and to previously unrecognised conditions that interfere with vitamin K absorption (CDC, 2025).
McNinch and Tripp's prospective surveillance across the British Isles, published in 1991, recorded 27 confirmed or probable cases between December 1987 and March 1990. Of these infants, 24 were solely breastfed, 10 experienced intracranial haemorrhage and two died; 20 had received no prophylaxis and seven had received the oral regimen then in use. Relative to intramuscular prophylaxis, the study reported risk ratios of 81:1 with no prophylaxis and 13:1 with that oral approach. Those figures describe the prophylaxis practices and formulations used in that historical setting, so they should not be treated as universal estimates for every modern oral regimen.
No single symptom pattern reliably identifies VKDB before it becomes serious. Reported signs include bruising, bleeding from the nose or umbilicus, pallor, blood in stool or urine, seizures and altered behaviour, yet an infant may have none of these before an internal haemorrhage. MedlinePlus (2025) describes the possible manifestations, and CDC (2025) states that most affected infants do not show a warning sign before a life-threatening bleed.
Source | Design / population | Key observation | What it supports |
Puckett & Offringa, 2000 | Cochrane review; 13 included trials | Clinical bleeding was reported in two of the included trials | IM prophylaxis lowered first-week bleeding; randomised trials did not assess late VKDB. |
McNinch & Tripp, 1991 | Prospective British Isles surveillance; 27 cases | 10 intracranial haemorrhages; 20 infants had received no prophylaxis | Late-disease risk in this surveillance study was much greater without IM prophylaxis. |
Sankar et al., 2016 | Systematic review of trials and surveillance studies | Median late-VKDB burden without prophylaxis: 35 per 100,000 live births | Four surveillance studies were found; the two with complete data yielded pooled RR 0.02 for parenteral prophylaxis versus none. |
Warren et al., 2013 | Tennessee cluster investigation; 4 confirmed cases | Three intracranial haemorrhages; all four families had declined IM vitamin K | Documents severe late VKDB in infants who had appeared healthy before presentation. |
Ardell et al., 2018 | Cochrane review in preterm infants | No eligible trial compared prophylaxis with no treatment | Preterm infants show low vitamin K status, but trials do not establish the best dose or route. |
Why the vitamin K shot is given at birth
What the randomised trials established
Randomised evidence is clearest for bleeding during the first week of life. Puckett and Offringa (2000) included 13 trials in their Cochrane review, but only two placebo or no-treatment comparisons of intramuscular vitamin K reported clinical bleeding outcomes. Intramuscular prophylaxis reduced bleeding during days 1–7, while both oral and intramuscular routes improved laboratory indicators of coagulation. The distinction between a laboratory response and a clinical bleeding outcome matters, and these trials did not test prevention of late VKDB.
Late VKDB has not been evaluated in a randomised prophylaxis-versus-no-prophylaxis trial. Sankar and colleagues (2016) therefore combined the randomised evidence relevant to classic disease with observational surveillance data for the late form. In settings without prophylaxis, the median reported burden was 35 cases per 100,000 live births; four surveillance studies were located, and the two with complete data produced a pooled relative risk of 0.02 for parenteral prophylaxis versus none. The large observed association favours prophylaxis, but the review judged the late-VKDB evidence to be low quality because it came from observational studies rather than random allocation.
What surveillance and policy add
Surveillance provides outcome information that the randomised trials do not. Warren and colleagues (2013) described a Tennessee cluster in which four infants, previously considered healthy, developed late VKDB between 6 and 15 weeks after their families declined intramuscular prophylaxis. Three had diffuse intracranial haemorrhage and the fourth had gastrointestinal bleeding. The report is useful for describing severe presentations, but a four-case cluster cannot establish national incidence or a causal effect by itself; that distinction is why case investigations and surveillance are interpreted differently from controlled trials.
Current paediatric guidance favours intramuscular prophylaxis at birth. The American Academy of Pediatrics statement by Hand, Noble and Abrams (2022) identifies parenteral vitamin K as the most effective method for preventing VKDB in newborn and young infants. ESPGHAN similarly recommends prophylaxis for every newborn and prefers intramuscular administration because of its efficiency and reliability (Mihatsch et al., 2016). These recommendations are not based on a single decisive experiment; they integrate first-week trial outcomes, late-disease surveillance and the practical reliability of different prophylaxis routes.
Why the evidence is not a modern placebo trial
A lack of modern placebo-controlled trials for late VKDB does not mean the preventive question is unsupported. Randomisation has not been used to test late VKDB directly, so outcome estimates for this form come from surveillance comparing different prophylaxis practices. These designs answer different questions: trials test short-term effects under controlled allocation, while surveillance observes rare outcomes across large populations. The older trials inform classic VKDB, whereas observational population data provide the main evidence for late disease (Puckett & Offringa, 2000; Sankar et al., 2016).
The evidence comes from different study designs, each answering a narrower question. Trials show less first-week bleeding and improved coagulation measures after prophylaxis, surveillance records markedly lower late-VKDB rates where parenteral prevention is used, and case investigations often involve infants who received no prophylaxis. Agreement across those sources strengthens the overall inference even though each design has its own limitations. Taken together, the independent lines of evidence support the same preventive conclusion without relying on a single comprehensive modern experiment (McNinch & Tripp, 1991; Warren et al., 2013).
Newborn physiology creates a short period of unusually low vitamin K reserve; prophylaxis substantially lowers the chance that serious bleeding is the first indication of that vulnerability.
Premature infants and the evidence gap
Preterm infants have several reasons to merit separate consideration. Their vitamin K stores may be smaller, enteral feeding can be delayed, intestinal colonisation develops differently, and both hepatic and haemostatic systems are immature. Neonatal intensive care can also alter feeding, antibiotic exposure and the timing of routine procedures, making this population unlike healthy term newborns in several respects. The AAP policy statement from 2022 therefore discusses preterm infants separately (Hand et al., 2022).
Direct trial evidence in preterm infants remains sparse. The Cochrane review by Ardell and colleagues (2018) found no prophylaxis-versus-no-treatment study and only one eligible comparison of administration strategies. Low vitamin K concentrations and proteins induced by vitamin K absence were documented during the first week, but these are biological markers rather than direct measurements of VKDB prevention. The evidence did not establish an optimal route or amount; the review rated it as low quality and noted the reliance on extrapolation from term infants.
The broad effectiveness of newborn prophylaxis should not be confused with equally strong evidence for every gestational-age subgroup. For preterm infants, no randomised trial in the Cochrane review established the appropriate dose and route. This leaves a firmer answer to whether prevention is needed than to which regimen is best for the smallest babies. Ardell et al. (2018) specifically identified infants born before 30 weeks' gestation as a group in need of further study.
What is proven about vitamin K deficiency and what remains uncertain
The central findings are supported by several types of evidence. Vitamin K is needed to activate clotting proteins, newborn reserves are small because placental transfer is limited, and human milk contributes relatively little; when deficiency becomes severe, VKDB may involve the gut, skin or intracranial space (Office of Dietary Supplements, 2026; CDC, 2025). These biological facts explain susceptibility but do not by themselves prove that a preventive intervention works. That conclusion comes from clinical evidence: randomised trials support intramuscular prophylaxis against classic VKDB, while surveillance consistently associates prophylaxis with a far lower occurrence of late disease (Puckett & Offringa, 2000; Sankar et al., 2016).
Important uncertainties remain at the edges of that evidence. Late VKDB prevention has not been tested in a randomised prophylaxis-versus-no-prophylaxis trial, so its clinical outcome evidence is observational. Preterm infants are another gap because direct trials have not settled the best administration strategy (Ardell et al., 2018). Oral prophylaxis adds separate complexity because effectiveness depends on formulation, repeat dosing and follow-up, so historical oral regimens cannot simply be treated as interchangeable with current national policies (Mihatsch et al., 2016; Sutor et al., 1999).
The epidemiology differs from that of iron deficiency, which affects many age groups more commonly; clinically significant vitamin K deficiency is unusual in healthy adults and is concentrated in particular risk settings. Related nutrient evidence is collected in the nutrition section. The practical takeaway is therefore specific rather than sweeping: evidence strongly supports preventing newborn VKDB, but it is less complete when the question shifts to the best route, timing or regimen for particular subgroups. Those narrower decisions depend more heavily on observational evidence, historical comparisons and professional guidance than on modern randomised clinical outcomes.
Frequently asked questions
Can vitamin K deficiency happen in adults?
Yes, but clinically significant deficiency is rare in healthy adults eating a varied diet. When it does occur, it is usually linked to conditions that reduce fat absorption, gastrointestinal disease, bariatric surgery or medicines that interfere with vitamin K metabolism. Severe deficiency can prolong clotting time and cause bruising or bleeding.
Does breastfeeding cause vitamin K deficiency?
Breastfeeding is not itself a disease or a reason to avoid human milk. The relevant point is that breast milk naturally contains relatively little vitamin K, while newborn stores are already low. In infants who have not received effective prophylaxis, exclusive breastfeeding is therefore one factor associated with late VKDB.
Can a newborn look healthy before VKDB starts?
Yes. Late VKDB can occur in infants who appeared healthy beforehand, and warning bleeding may be absent. CDC guidance describes intracranial bleeding as a common presentation of late disease. That is one reason prevention is offered before symptoms appear rather than waiting for a visible sign of deficiency.
Is VKDB the same as haemophilia?
No. VKDB is an acquired bleeding disorder caused by inadequate activity of vitamin K-dependent clotting factors and can be corrected by restoring vitamin K. Haemophilia is usually an inherited deficiency of a specific clotting factor. The disorders can both cause bleeding, but their causes, laboratory patterns and long-term implications differ.
Why is late VKDB considered especially dangerous?
Late VKDB is uncommon, but a substantial share of reported cases involve bleeding inside the skull. Intracranial haemorrhage can begin without an obvious external warning sign and may cause neurological injury or death. The severity of those outcomes is central to why newborn prophylaxis is treated as a preventive public-health measure.
Sources
- Puckett RM, Offringa M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. Cochrane Database of Systematic Reviews. 2000;(4):CD002776. DOI 10.1002/14651858.CD002776. https://www.cochrane.org/evidence/CD002776_prophylactic-vitamin-k-vitamin-k-deficiency-bleeding-neonates
- Ardell S, Offringa M, Ovelman C, Soll R. Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates. Cochrane Database of Systematic Reviews. 2018;(2):CD008342. DOI 10.1002/14651858.CD008342.pub2. https://www.cochrane.org/evidence/CD008342_prophylactic-vitamin-k-prevention-vitamin-k-deficiency-bleeding-preterm-neonates
- Sankar MJ, Chandrasekaran A, Kumar P, Thukral A, Agarwal R, Paul VK. Vitamin K prophylaxis for prevention of vitamin K deficiency bleeding: a systematic review. Journal of Perinatology. 2016;36(Suppl 1):S29–S35. DOI 10.1038/jp.2016.30.
- McNinch AW, Tripp JH. Haemorrhagic disease of the newborn in the British Isles: two year prospective study. BMJ. 1991;303(6810):1105–1109. DOI 10.1136/bmj.303.6810.1105.
- Warren M, Miller A, Traylor J, Sidonio R, Morad A, Goodman A, Christensen D, Grant A, Odom E, Okoroh E, Clayton J, Maenner M, Marcewicz L. Notes from the Field: Late Vitamin K Deficiency Bleeding in Infants Whose Parents Declined Vitamin K Prophylaxis - Tennessee, 2013. MMWR Morbidity and Mortality Weekly Report. 2013;62(45):901–902. https://pmc.ncbi.nlm.nih.gov/articles/PMC4585350/
- Hand I, Noble L, Abrams SA; Committee on Fetus and Newborn, Section on Breastfeeding, Committee on Nutrition. Vitamin K and the Newborn Infant. Pediatrics. 2022;149(3):e2021056036. DOI 10.1542/peds.2021-056036.
- Zipursky A. Prevention of vitamin K deficiency bleeding in newborns. British Journal of Haematology. 1999;104(3):430–437. DOI 10.1046/j.1365-2141.1999.01104.x.
- Sutor AH, von Kries R, Cornelissen EAM, McNinch AW, Andrew M. Vitamin K deficiency bleeding (VKDB) in infancy. ISTH Pediatric/Perinatal Subcommittee. International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. 1999;81(3):456–461. DOI 10.1055/s-0037-1614494.
- Mihatsch WA, Braegger C, Bronsky J, et al. Prevention of Vitamin K Deficiency Bleeding in Newborn Infants: A Position Paper by the ESPGHAN Committee on Nutrition. Journal of Pediatric Gastroenterology and Nutrition. 2016;63(1):123–129. DOI 10.1097/MPG.0000000000001232.
- Office of Dietary Supplements, National Institutes of Health. Vitamin K: Fact Sheet for Health Professionals. 22 October 2026. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/
- Centers for Disease Control and Prevention. How to Protect Babies from Life-threatening Bleeding. 17 January 2025. https://www.cdc.gov/vitamin-k-deficiency/hcp/fact-sheet/
- MedlinePlus Medical Encyclopedia. Vitamin K deficiency bleeding of the newborn. 3 October 2025. https://medlineplus.gov/ency/article/007320.htm
This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.
Related
Vitamin K and why your body needs it for healthy bones
Iron deficiency and how it affects your health
Vitamin C benefits and the common cold myth that won't go away
What potassium does for the body, from heartbeat to blood pressure
Vitamin B12 deficiency and the signs you should know
What research shows about whether creatine is bad for your kidneys
Magnesium for anxiety and what the clinical trials actually found